Systemic lupus erythematosus (SLE) affects multiple organs and is characterized by chronic inflammation and immune system dysregulation. Current treatments focus on immunosuppressive therapies, but these can have limitations in efficacy and long-term safety. Mesenchymal stem cells (MSCs) have emerged as a potential therapeutic option due to their immunomodulatory properties.
A systematic review published in AIP Conference Proceedings examined clinical trials on the effects of MSC therapy in SLE patients. The review analyzed studies from 2012 to 2022, selecting human clinical trials involving patients aged 18 and older. Researchers assessed the data using the Cochrane Risk Bias Assessment Tool and graded the quality of the studies with the GRADE system to ensure reliability.
Key findings from the review indicate that MSC therapy may offer benefits for lupus patients, including:
- Reduction in Autoantibodies: MSCs may help decrease the levels of autoantibodies, which play a role in disease progression.
- Lower Proinflammatory Cytokine Levels: The therapy appears to reduce inflammation by modulating immune responses.
- Potential Restoration of Clinical Function: Some studies suggest that MSC therapy may contribute to improved disease management and symptom relief.
